Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Patient Preference × pazopanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 58 Sarcoma 34 Neoplasms 20 Neoplasm Metastasis 19 Breast Neoplasms 17 Ovarian Neoplasms 15 Carcinoma, Non-Small-Cell Lung 13 Leiomyosarcoma 6 Kidney Neoplasms 6 Hemangiosarcoma 6 Thyroid Neoplasms 5 Recurrence 5 Melanoma 5 Lung Neoplasms 5 Liposarcoma 5 Glioblastoma 5 Fallopian Tube Neoplasms 5 Urinary Bladder Neoplasms 4 Prostatic Neoplasms 4 Pancreatic Neoplasms 4 Osteosarcoma 4 Neurofibrosarcoma 4 Clear-cell metastatic renal cell carcinoma 4 Sarcoma, Synovial 3 Sarcoma, Alveolar Soft Part 3 Neuroendocrine Tumors 3 Histiocytoma, Malignant Fibrous 3 Gliosarcoma 3 Gastrointestinal Stromal Tumors 3 Fibrosarcoma 3

Interventions

pertuzumab 1 pazopanib 1 enzalutamide 1 delta 24-sterol reductase 1 decitabine and cedazuridine drug combination 1 daratumumab 1 apalutamide 1 Validation Studies as Topic 1 Trastuzumab 1 Tape Recording 1 Surgical Procedures, Operative 1 Sunitinib 1 Radiotherapy 1 Pilot Projects 1 Opdualag 1 Nivolumab 1 Injections, Subcutaneous 1 Focus Groups 1 Bandages, Hydrocolloid 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01064310 2017-04-17

PISCES

Novartis

Phase 3 Completed

169 enrolled 16 charts

Carcinoma, Renal Cell, Neoplasms, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon ⚡